Safety of opicapone after 5 years of post-marketing experience worldwide
Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson’s Disease
Objective: This study aims to explore the potential of once-daily opicapone (OPC) 50 mg to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi)…OCEAN Study in Parkinson’s Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone
Objective: This study aims to evaluate if treatment with opicapone (OPC) 50 mg once-daily can improve motor fluctuation (MF)-related pain in patients with Parkinson’s disease…The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study
Objective: To describe the real-world use of catechol-O-methyltransferase (COMT) inhibitors add on to levodopa/dopa decarboxylase inhibitor (DDCI) in patients with Parkinson’s disease (PD) suffering from…Early Morning Dystonia in Parkinson’s Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I
Objective: This study evaluated the effect of once-daily opicapone (OPC) 50 mg versus entacapone (ENT) on Early Morning Dystonia (EMD) in Parkinson’s disease patients with…Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations
Objective: This study compared the effects of catechol-O-methyl transferase (COMT) inhibitors and monoamine oxidase‑B (MAO-B) inhibitors on mean change from baseline to end-of-study in OFF-time…OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…The effect of co-administration of opicapone on the pharmacokinetics of levodopa
Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center
Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »